# Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer

> **NCT00192036** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 49 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** cisplatin
- **RADIATION:** radiation

## Key facts

- **NCT ID:** NCT00192036
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2008-01
- **Final completion:** 2009-11
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2010-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192036, "Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00192036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*